Evaluating the Safety and Effectiveness of BI 765423 Infusion in Adults 40 and Older with Idiopathic Pulmonary Fibrosis

What this Trial Is About

This research is focused on adults aged 40 and older who have idiopathic pulmonary fibrosis IPF, a lung condition characterized by scarring and reduced lung function. The study aims to evaluate whether the medicine BI 765423 can improve lung capacity compared to a placebo. Participants must have certain lung function levels and evidence of lung fibrosis confirmed by imaging to join the study. Participants are randomly assigned to one of two groups one receives BI 765423 through an intravenous infusion every four weeks, and the other receives a placebo that looks the same but contains no active medicine. The study lasts up to 11 months, during which participants may continue their standard IPF treatments. The main treatment period focuses on observing changes in lung function over 3 to 6 months. During the trial, participants visit the study site several times for screening, treatment, and follow-up assessments. Doctors measure lung function with tests like forced vital capacity FVC and collect blood samples to monitor markers of lung health. The study compares results between the groups to assess the effects of BI 765423, while also monitoring participants overall health and any side effects.

A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment